Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)428.70
  • Today's Change-0.70 / -0.16%
  • Shares traded144.08k
  • 1 Year change+6.46%
  • Beta0.5727
Data delayed at least 15 minutes, as of Sep 15 2026 15:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2025202520242023
ASSETS
Cash And Short Term Investments296284155
Total Receivables, Net915863583
Total Inventory772721487
Prepaid expenses------
Other current assets, total01245
Total current assets1,9831,8791,269
Property, plant & equipment, net2,9982,9681,653
Goodwill, net6,1935,605265
Intangibles, net4,8964,419343
Long term investments314336
Note receivable - long term5.906.005.77
Other long term assets------
Total assets16,34915,1963,809
LIABILITIES
Accounts payable421423217
Accrued expenses----110
Notes payable/short-term debt000
Current portion long-term debt/capital leases1,702266426
Other current liabilities, total619399222
Total current liabilities2,7411,088974
Total long term debt1,3041,530612
Total debt3,0051,7971,037
Deferred income tax1,3161,256264
Minority interest--050
Other liabilities, total13314534
Total liabilities5,4944,0201,934
SHAREHOLDERS EQUITY
Common stock12612675
Additional paid-in capital------
Retained earnings (accumulated deficit)11,15911,0321,845
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(429)18(45)
Total equity10,85511,1761,875
Total liabilities & shareholders' equity16,34915,1963,809
Total common shares outstanding466466277
Treasury shares - common primary issue2.382.163.68
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.